


>>>>

| 2025
(Pharmacy)

GNIPST BULLETIN

Volume-3, Issue- 1



**GURU NANAK INSTITUTE OF PHARMACEUTICAL
SCIENCE AND TECHNOLOGY**


157/F, Nilgunj Road, Kolkata- 700114, West Bengal, India



Table of Contents

- 01** Message from Director and Principal
- 02** Recent Researches
- 03** New Drug Approvals
- 04** Clinical Trial News
- 05** Disease Outbreak News
- 06** Campus News
- 07** Special Page and Game time





MESSAGE FROM HONORABLE DIRECTOR

As the Director of Guru Nanak Institute of Pharmaceutical Science and Technology, I extend my heartfelt greetings to our academic community and well-wishers on the occasion of World Environment Day.

This day serves as a powerful reminder of our shared responsibility to protect our planet and reaffirms our commitment to sustainability, innovation, and scientific excellence. At GNIPST, we are devoted to nurturing inquisitive minds, fostering environmental awareness, and

reshaping our students into future leaders in Pharmaceutical Sciences—driven by the vision of a healthier society and a greener future.

Let us step forward with renewed enthusiasm, a spirit of collaboration, and unwavering dedication to advancing global well-being while safeguarding the environment.

Wishing you and your families good health, peace, progress, and fulfillment in all your endeavors.

Prof. (Dr.) Ashijit Sengupta



MESSAGE FROM HONORABLE PRINCIPAL

I extend my warm greetings and best wishes to our students, faculty, staff, alumni, and valued partners on the occasion of World Environment Day. May the days ahead bring peace, prosperity, good health, and a renewed commitment to environmental responsibility in every aspect of life.

At Guru Nanak Institute of Pharmaceutical Science and Technology (GNIPST), we remain steadfast in our pursuit of academic excellence, inclusive growth, and sustainability. Since our inception in 2005, GNIPST has evolved into a distinguished center for pharmacy education—recognized by the Pharmacy Council of India (PCI) and honored as the first pharmacy institution in the region to achieve both NAAC and NBA accreditations. Our recent achievement of securing the 74th rank in NIRF 2024 is a testament to our dedication to quality education and professional advancement.

As we move forward, we reaffirm our mission to nurture intellectual curiosity, foster innovation, and prepare our students to be not only leaders in pharmaceutical sciences but also conscientious global citizens committed to environmental stewardship.

We take pride in cultivating a culture that encourages personal growth, leadership, and a deep sense of responsibility towards society and the environment.

Let us advance together with integrity, passion, and a shared vision—working for a healthier planet and a sustainable future.

Wishing you continued success, fulfillment, and meaningful accomplishments on this important day and beyond.



Prof. (Dr.) Lopamudra Datta





RECENT RESEARCHES



WHO calls for urgent action to ban flavoured tobacco and nicotine products

MORE INFO

www.who.int/

On World No Tobacco Day, the World Health Organization (WHO) today launches a new publication and calls on governments to urgently ban all flavours in tobacco and nicotine products, including cigarettes, pouches, hookahs and e-cigarettes, to protect youth from addiction and disease. Flavours like menthol, bubble gum and cotton candy are masking the harshness of tobacco and nicotine products turning toxic products into youth-friendly bait. Flavours not only make it harder to quit but have also been linked to serious lung diseases. Cigarettes, which still kill up to half of their users, also come in flavours or can have flavours added to them.

WHO outlines recommendations to protect infants against RSV – respiratory syncytial virus

MORE INFO

www.who.int/

Today, the World Health Organization (WHO) published its first-ever position paper on immunization products to protect infants against respiratory syncytial virus (RSV) – the leading cause of acute lower respiratory infections in children globally. Every year, RSV causes about 100 000 deaths and over 3.6 million hospitalizations in children under the age of 5 years worldwide. About half of these deaths occur in infants younger than 6 months of age. The vast majority (97%) of RSV deaths in infants occur in low- and middle-income countries where there is limited access to supportive medical care, such as oxygen or hydration. Published in the Weekly Epidemiological Record (WER), the position paper outlines WHO recommendations for two immunization products: a maternal vaccine that can be given to pregnant women in their third trimester to protect their infant and a long-acting monoclonal antibody that can be administered to infants from birth, just before or during the RSV season.

Gloves do not replace hand hygiene – reminder from WHO

MORE INFO

www.who.int/

Hand hygiene is one of the most effective, affordable and universal tools we have to prevent the transmission of infections and provide high-quality, clean and safe medical care. While medical gloves serve a vital role in preventing transmission of infection, for example when there is risk of exposure to blood and body fluids, they are not a substitute for cleaning hands at the right time. On this World Hand Hygiene Day, the World Health Organization (WHO) urges governments, health-care facilities, and frontline workers around the world to reinforce hand hygiene practices – a proven, cost-effective intervention to protect both patients and health-care workers.

FDA



NEW DRUG APPROVALS

June, 2025

Enflonsia (clesrovimab-cfor) Injection

- Date of Approval: June 9, 2025
- Company: Merck
- Treatment for: RSV Vaccination and Immunization



Ibtrozi (taletrectinib) Capsules

- Date of Approval: June 11, 2025
- Company: Nuvation Bio Inc.
- Treatment for: Non Small Cell Lung Cancer



Xifyrm (meloxicam) Injection

- Date of Approval: June 5, 2025
- Company: Azurity Pharmaceuticals, Inc.
- Treatment for: Pain



Arynta (lisdexamfetamine dimesylate) Oral Solution

- Date of Approval: June 16, 2025
- Company: Azurity Pharmaceuticals, Inc.
- Treatment for: ADHD, Binge Eating Disorder



Zusduri (mitomycin) for Intravesical Solution – formerly UGN-102

- Date of Approval: June 12, 2025
- Company: UroGen Pharma Ltd.
- Treatment for: Bladder Cancer



Harliku (nitisinone) Tablets

- Date of Approval: June 19, 2025
- Company: Cycle Pharmaceuticals
- Treatment for: Alkaptonuria



Yeztugo (lenacapavir) Tablets and Injection

- Date of Approval: June 18, 2025
- Company: Gilead Sciences, Inc.
- Treatment for: Pre-Exposure Prophylaxis of HIV



<https://www.drugs.com/newdrugs.html>



CLINICAL TRIAL NEWS

**01.**

Johnson & Johnson Unveils First-in-Human Results for Pasritamig, Showing Early Anti-Tumor Activity in Prostate Cancer

JUNE 1, 2025 – Johnson & Johnson announced today new data from a Phase 1 study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific antibody that activates T-cells to harness the body's immune system against prostate cancer cells, showing promise in patients with advanced disease who have progressed after multiple lines of therapy. These first data on pasritamig, from the first-in-human study, demonstrate that pasritamig appears well-tolerated and exhibits a promising antitumor activity in patients with metastatic castration-resistant prostate cancer (mCRPC), highlighting the potential of KLK2 as a novel target for T-cell engagement in advanced disease.

02.

Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy

June 02, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that the primary endpoint was met in the ORIGIN Phase 3 trial of atacicept for the treatment of immunoglobulin A nephropathy (IgAN) in adults.

03.

Collectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)

June 04, 2025 (GLOBE NEWSWIRE) -- Collectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for iopofosine I 131, a potential first-in-class, novel cancer targeting agent utilizing a phospholipid ether as a radioconjugate monotherapy, for the treatment of relapsed/refractory Waldenstrom macroglobulinemia (r/r WM).

04.

Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases

June 11, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for RAD101 to distinguish between recurrent disease and treatment effect of brain metastases originating from solid tumors of different origin including leptomeningeal disease.

05.

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations

June 23, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to daraxonrasib, the company's RAS(ON) multi-selective inhibitor, for previously treated metastatic PDAC in patients with KRAS G12 mutations. The Breakthrough Therapy Designation is based on encouraging data from the Phase 1 RMC-6236-001 clinical trial evaluating daraxonrasib in patients with previously treated metastatic PDAC.

06.

AQuoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome

June 24, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the Company's lead asset, QRX003, for the treatment of Netherton Syndrome.

07.

Breast Cancer Risk in Younger Women May Be Influenced by Hormone Therapy

June 30, 2025 -- Scientists at the National Institutes of Health (NIH) have found that two common types of hormone therapy may alter breast cancer risk in women before age 55. Researchers discovered that women treated with unopposed estrogen hormone therapy (E-HT) were less likely to develop the disease than those who did not use hormone therapy.

MORE INFORMATION

https://www.drugs.com/clinical_trials_archive/january-2025.html



DISEASE OUTBREAK NEWS (DONS)


July, 2025

Avian Influenza A(H5N1) - Cambodia

5 July 2025

Situation at a glance

Between 1 January and 1 July 2025, the World Health Organization (WHO) was notified by Cambodia's International Health Regulations (IHR) National Focal Point (NFP) of 11 laboratory-confirmed cases of human infection with avian influenza A(H5N1) virus. Seven of the 11 cases were reported in June, an unusual monthly increase. Avian influenza A(H5N1) was first detected in Cambodia, in December 2003, initially affecting wild birds. Since then, 83 cases of human infection with influenza A(H5N1), including 49 deaths (case fatality ratio [CFR] of 59%), have been reported in the country. While the virus continued to circulate in avian species, no human cases were reported between 2014 and 2022, after which, the virus re-emerged in humans in February 2023. Since the re-emergence of human A(H5N1) infections in Cambodia in 2023, a total of 27 cases have been reported (six in 2023, 10 in 2024, and 11 to date in 2025), of which 12 were fatal (CFR 44%). Seventeen of the cases occurred in children under 18 years old. Avian influenza A(H5N1) is circulating in wild birds, poultry and some mammals around the world, and occasional human infections following exposure to infected animals or contaminated environments are expected to occur. In cases detected in Cambodia, exposure to sick poultry, often poultry kept in backyards, has been reported. According to the IHR, a human infection caused by a novel influenza A virus subtype is an event that has the potential for high public health impact and must be notified to the WHO. Based on currently available information, WHO assesses the current risk to the general population posed by this virus as low. For those occupationally exposed to the virus, such as farm workers, the risk is low to moderate, depending on the measures in place. WHO routinely reassesses this risk to factor in new information.



MORE
INFO

<https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON573>

Rabies - Timor-Leste

24 July 2025

Situation at a glance

On 17 May 2025, the Timor-Leste government reported to the World Health Organization (WHO) a fatal human case of rabies from Ermera Municipality. Between May and mid-June 2025, Timor-Leste confirmed four human rabies deaths in the municipalities of Bobonaro (n=2), Ermera (n=1) and Oecusse (n=1). All cases involved individuals exposed to dogs' bites months prior to symptom onset, with rabies virus confirmed via Reverse Transcription Polymerase Chain Reaction (RT-PCR) testing. Since March 2024, a total of 106 animal rabies cases—mostly in dogs—have been reported, and over 1400 dog bites or scratches have occurred, with a total of six fatalities. Access to and completion of post-exposure prophylaxis remains limited. The spread of rabies into non-border areas like Ermera signals a growing public health concern. The public health response is ongoing and includes vaccination of dogs, risk communication, training of healthcare workers on Post-Exposure Prophylaxis (PEP) and case management, active surveillance, and ensuring the availability of rabies vaccines and human rabies immunoglobulin. Based on the current available information, the WHO assesses the risk posed by this event as high at the national level, moderate at the regional level, and low at the global level.

Description of the situation



MORE
INFO

<https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON566>

CAMPUS NEWS



1. Industrial Training: GNIPST is delighted to announce that 5 students of B. Pharm 4th Year have successfully completed their 15-day Industrial Training at Mankind Pharma. This training provided them with valuable insights into real-world pharmaceutical manufacturing, quality control, and industry operations.



3. National Seminar: GNIPST organized a National Seminar on "Intellectual Property – Procedures and Issues" on 29th July 2025 in offline mode. The seminar brought together students, faculty, and experts to engage in insightful discussions on the legal, procedural, and practical aspects of Intellectual Property Rights.



2. National Seminar: The Social Welfare Club of GNIPST organized a National Seminar and Health Awareness Program on Hair Loss and Skin Care, in collaboration with Dr. Reddy's Foundation for Health Education and Dr. Reddy's Laboratories Ltd. We were honoured to have Dr. Debashish Biswas (MBBS, DIP & Fellowship in Aesthetic Medicine, DIP Trichology), Founder of Radiant Esthetics, Kolkata, and Medical Director at Thermaderm Skin, as our esteemed speaker.



4. Field Visit: An Field visit to the Acharya Jagadish Chandra Bose Indian Botanic Garden, Shibpur, Howrah was organized for the Diploma in Pharmacy students by the Faculty of Guru Nanak Institute of Pharmaceutical Science and Technology. The visit aimed to provide practical exposure to medicinal plants and enhance students' understanding of pharmacognosy, a core subject in the pharmacy curriculum. During the visit, students were introduced to the identification, classification, and uses of several plant species. Faculty members provided detailed explanations of the phytochemical constituents, therapeutic applications, and habitat requirements of the plants. The visit also included an interactive session where students asked questions and noted the botanical names, families, and key constituents of the herbs they observed.




INTERNATIONAL CHESS DAY

Celebrating International Chess Day on July 20, 2025, India shines with remarkable global chess achievements. Young stars like Praggnanandhaa Rameshbabu, Arjun Erigaisi, D Gukesh, and Divya Deshmukh have secured landmark victories and world titles, elevating India's status in international chess. Praggnanandhaa reached World No.4 with a Tata Steel win, while Arjun joined the elite 2800+ rating club, showcasing India's growing pool of top grandmasters. D Gukesh made history as the youngest World Chess Champion and earned the prestigious Khel Ratna award. The national team's gold at the 2025 FIDE World Rapid Team Championship reflects India's collective strength. On the women's front, Divya Deshmukh's world title and four Indian women ranking in the global top 20 highlight India's rising dominance. These achievements boost chess infrastructure, media attention, and inspire countless young players nationwide to pursue excellence and dream big.



GNIPST GAME TIME



Word search (Hint: Drug names)

P	E	N	I	C	I	L	L	I	N
B	L	O	R	A	Z	E	P	A	M
N	D	W	P	R	J	S	B	Z	O
R	F	T	U	B	J	E	N	V	I
P	K	M	P	I	D	K	U	T	U
S	T	U	M	M	G	H	R	T	Y
O	D	P	R	A	Z	O	C	I	N
T	O	L	A	Z	A	M	I	D	E
Q	L	E	V	O	D	O	P	A	
M	C	V	R	L	O	R	U	P	W
S	A	Q	I	E	S	X	K	H	F

Stay tuned for to the next edition for a shout out to fastest correct answers!

Submit your answer



or



Cheers to the Victor!

Volume -2, Issue -6



Shreya Mondal

B.Pharm, 5th Semester

Editorial Board

Editor- in- Chief

Prof. (Dr.) Abhijit Sengupta

Managing Editors

Prof. (Dr.) Lopamura Datta

Associate Editors

Mr. Tushar Adhikari

Ms. Manjarima Ganguli

Editorial Board Members

Mrs. Indrani Banerjee Chakraborty

Mr. Arpan Dutta

Ms. Ananya Chandra

Ms. Parnasree Chakraborty

Ms. Lopamudra Saha

Mr. Sarthak Saha



COURSES OFFERED

PHARMACY UG COURSES

- Bachelor of Pharmacy (B.Pharm)

PHARMACY DIPLOMA COURSES

- Diploma in Pharmacy (D.Pharm)

PHARMACY PG COURSES

- M.Pharm in Pharmaceutics
- M.Pharm in Pharmacology
- M.Pharm in Pharmaceutical Chemistry
- M.Pharm in Quality assurance
- M.Pharm in Regulatory Affairs
- M.Pharm in Pharmacognosy
- M.Pharm in Pharmaceutical Biotechnology

Major
Recruiters



**Latest
news**



www.gnipst.ac.in



www.facebook.com



www.instagram.com



www.linkedin.com



www.youtube.com



api.whatsapp.com